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Abstract 
Startle disease is a rare, potentially fatal neuromotor disorder characterized by exaggerated 
startle reflexes and hypertonia in response to sudden unexpected auditory, visual or tactile 
stimuli. Mutations in the GlyR α1 subunit gene (GLRA1) are the major cause of this disorder, 
since remarkably few individuals with mutations in the GlyR β subunit gene (GLRB) have 
been found to date. Systematic DNA sequencing of GLRB in individuals with hyperekplexia 
revealed new missense mutations in GLRB, resulting in M177R, L285R and W310C 
substitutions. The recessive mutation M177R results in the insertion of a positively-charged 
residue into a hydrophobic pocket in the extracellular domain, resulting in an increased EC50 
and decreased maximal responses of α1β GlyRs. The de novo mutation L285R results in the 
insertion of a positively-charged side chain into the pore-lining 9’ position. Mutations at this 
site are known to destabilize the channel closed state and produce spontaneously active 
channels. Consistent with this, we identified a leak conductance associated with spontaneous 
GlyR activity in cells expressing α1β
L285R GlyRs. Peak currents were also reduced for α1β
L285R 
GlyRs although glycine sensitivity was normal. W310C was predicted to interfere with 
hydrophobic side-chain stacking between M1, M2 and M3. We found that W310C had no 
effect on glycine sensitivity, but reduced maximal currents in α1β GlyRs in both homozygous 
(α1β
W310C) and heterozygous (α1ββ
W310C) stoichiometries. Since mild startle symptoms were 
reported in W310C carriers, this may represent an example of incomplete dominance in 
startle disease, providing a potential genetic explanation for the ‘minor’ form of hyperekplexia. 
 
Keywords: GLRA1; GLRB; glycine receptor; hyperekplexia; startle disease 
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Introduction 
Inhibitory glycine receptors (GlyRs) are ligand-gated chloride channels enriched in the spinal 
cord, brainstem and retina, consisting of heteropentameric combinations of ligand-binding 
GlyR α subunits (α1-α4) together with the GlyR β subunit (Lynch, 2009). Each GlyR subunit is 
composed of an N-terminal extracellular domain and four α-helical membrane-spanning 
domains (M1-M4). M3 and M4 are linked by a long intracellular domain containing binding 
sites for a variety of intracellular factors. Although GlyR α and β subunits both play an active 
role in agonist binding (Grudzinska et al. 2005; Dutertre et al. 2012), the GlyR β subunit was, 
until recently, widely assumed to play solely a structural role in heteromeric GlyRs. In part, 
this was due to the key role of the GlyR β subunit in mediating high-affinity interactions with 
the synaptic clustering molecule gephyrin (Meyer et al. 1995), which in turn controls the 
dynamic localization of GlyRs at synaptic sites (Feng et al. 1998). More recently, the GlyR β 
subunit was also reported to interact with the proteins Vacuolar Protein Sorting 35 (Vps35) 
and Neurobeachin (Nbea), indicating a new role in GlyR trafficking (del Pino et al. 2011). 
However, the atypical M2 domain of the GlyR β subunit also confers resistance to the effects 
of picrotoxinin (Pribilla et al. 1994) and the insecticide lindane (Islam and Lynch, 2012) as well 
as influencing the main-state single-channel conductances of heteromeric αβ GlyRs 
(Bormann et al. 1993). 
 
Initial cross-linking studies of affinity-purified native GlyRs suggested that heteromeric GlyRs 
exist in a 3α:2β subunit combination (Langosch et al. 1988). However, three innovative 
studies have recently revealed that the GlyR β subunit represents the major component of 
heteromeric GlyRs, which are more likely to exist in a 2α:3β stoichiometry. Grudzinska et al. 
2005 compared the effects of mutations affecting predicted glycine binding residues in GlyR 
α1 and β subunits. Co-expression of mutant GlyR α1 with wild-type β subunits resulted in a full 
rescue of the EC50 value for glycine, whilst co-expression of wild-type GlyR α1 with mutant β 
subunits resulted in a decrease in EC50. A subsequent study (Dutertre et al. 2012) revealed 
that the GlyR β subunit contributes more to agonist binding site formation than had been 
previously realized. Experiments with GlyR α1-β subunit concatemers also revealed that 
functional heteromeric GlyRs can be produced when these were co-expressed with GlyR β 
subunit monomers but not when expressed alone, or with GlyR α1 subunit monomers 
(Grudzinska et al. 2005). This result was consistent with either a 2α:3β or a 1α:4β 
stoichiometry. However, quantification of (35S)methionine incorporation into recombinant α1β 
versus α1 subunit GlyRs suggested a 2α:3β stoichiometry and the subunit order β-α-β-α-β. 
This stoichiometry and subunit arrangement has recently been confirmed by imaging single 
antibody-bound GlyR α1β heteromers using atomic force microscopy (Yang et al. 2012). 
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Defects in the adult GlyR isoform (α1β) also have an important role in disease. Mutations in 
GLRA1, encoding the GlyR α1 subunit, are the major genetic cause of startle 
disease/hyperekplexia in humans (Shiang et al. 1993, 1995; Chung et al. 2010) and cause 
similar disorders in mice (Buckwalter et al. 1994; Ryan et al. 1994; Holland et al. 2006; Traka 
et al. 2006) and Poll Hereford cattle (Pierce et al. 2001). In humans, hyperekplexia affects 
newborn children and is characterized by exaggerated startle reflexes and hypertonia in 
response to sudden, unexpected auditory, tactile or visual stimuli. By contrast, GLRB 
mutations are less frequent, but recessive mutations have been discovered in three families 
with hyperekplexia (Rees et al. 2002; Al-Owain et al. 2012; Lee et al. 2012), in the mouse 
mutant spastic (Kingsmore et al. 1994; Mülhardt et al. 1994) and the zebrafish bandoneon 
mutant (Hirata et al. 2005). However, one conundrum is why so few GLRB mutations are 
found in startle disease relative to GLRA1, or SLC6A5, encoding the presynaptic glycine 
transporter GlyT2, which are the primary and secondary genetic causes of startle disease 
respectively (Rees et al. 2006; Carta et al. 2012; Giménez et al. 2012). Here we report the 
characterization of three new missense mutations in GLRB, resulting in M177R, L285R and 
W310C substitutions in the extracellular domain, and the M2 and M3 membrane-spanning 
domains, respectively. We present detailed molecular modeling and functional analysis of 
these new GlyR β subunit mutations, revealing novel pathogenic mechanisms and modes of 
inheritance. 
 
Materials and Methods 
Patients and Cases 
49 individuals with a clinical diagnosis of hyperekplexia (non-habituating startle response, 
positive nose tap test, history of neonatal/infantile hypertonicity) but lacking mutations in 
GLRA1 and SLC6A5 were ascertained by referral from pediatricians from international 
centers. DNA analysis of GLRB was performed at the Laboratory for Diagnostic Genome 
Analysis (LDGA) of the Center of Human and Clinical Genetics of the Leiden University 
Medical Center. The LDGA is NEN-EN-ISO 15189:2007 accredited by the Dutch 
Accreditation Council. Informed consent for participation in the study and publication of 
clinical and genetic data was obtained by the referring clinicians (MV at Sahlgrenska 
University Hospital and FMC at Imperial College London).   
 
Genetic analysis 
DNA was extracted from whole blood taken from affected individuals and relatives using a 
Gentra Puregene DNA purification Kit (Gentra Systems, Minneapolis, USA). Primers 
recognizing the ten GLRB coding exons and flanking splice sites were designed using the 
Lightscanner Primer Design Software package, version 1 (Idaho Technology Inc, Salt Lake 
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City, Utah). To avoid allelic dropout, all primers were placed in intronic regions that were 
devoid of single-nucleotide polymorphisms (SNPs) as revealed by National Center for 
Biotechnology Information databases. Primer designs are provided in supplementary table 1. 
Amplified PCR fragments were sequenced on an ABI PRISM 3730 using the BigDye 
Terminator cycle sequencing ready reaction kit (Applied Biosystems, Foster City, CA, USA) 
and analyzed using SeqScap software for comparative sequence analysis (Applied 
Biosystems). Single nucleotide variants (SNVs) were assessed against those found in NCBI 
dbSNP Build 136 and release 20100804 from the 1000 genomes project. 
 
Homology modeling of the human GlyR 
Fold recognition of human GlyR α1 and β subunits was performed with HHPred (Söding et al. 
2005), identifying the structure of the C. elegans glutamate-gated chloride channel (GluCl; 
PDB: 3RHW) (Hibbs and Gouaux 2011) as the best template (p-value: 0). A profile-profile 
alignment between the human GlyR α1 subunit and the GluCl α subunit was generated using 
MUSCLE (Edgar 2004) and T-COFFEE (Notredame et al. 2000) resulting in 44.4% sequence 
identity. A separate alignment was generated for the human GlyR β subunit and GluCl 
resulting in 38.9% sequence identity. A short part of the sequence at the N-terminus of the β 
subunit (residues 1-30), and the extended loop region between M3 and M4 of both the α1 and 
β subunits (residues 312-396 and 337-453, respectively) could not be accurately modeled 
due to lack of sequence identity and were therefore removed. The two alignments were 
inspected manually and combined to include all five subunits together to re-create the entire 
pentameric structure in the stoichiometry 2α1:3β with the subunit arrangement β-α-β-α-β. 
Using MODELLER-9v10 (Eswar et al. 2003), 50 models were built based on the combined 
alignment, restraining disulfide bonds between the cysteine residues involved in the cys-loops 
within each subunit (C138-C152 and C198-C209 in the α1 subunit and C161-C175 and C221-
C233 in the β subunit). Each model was assessed by MODELLER with the Discrete 
Optimized Protein Energy (DOPE) statistical potential score (Shen and Sali, 2006) and the 
optimal model was selected based on the lowest score (normalized DOPE Z score: -0.222). A 
further assessment of model quality was performed using QMEAN (Benkert et al. 2011) The 
QMEAN Z score for the human GlyR α1β model was -3.43, indicating a reasonable model 
(Benkert et al. 2011). Selected non-synonymous substitutions were modeled into the GlyR 
homology model with the swapaa command in Chimera (Pettersen et al. 2004) using the 
Dunbrack backbone-dependent rotamer library (Dunbrack, 2002) and taking into account the 
lowest clash score, highest number of H-bonds and highest rotamer probability. 
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Site-directed mutagenesis and expression constructs 
Full-length human GlyR α1 and β subunits were cloned into the vector pRK5 as previously 
described (Chung et al. 2010). Mutations were introduced into pRK5-hGlyRβ using the 
QuikChange site-directed mutagenesis kit (Agilent). All expression constructs were confirmed 
by Sanger sequencing of the entire coding region. 
 
Cell surface biotinylation assays 
Wild-type or mutant GlyR α1β heteromers were transiently-expressed in human embryonic 
kidney (HEK293) cells transfected using magnetofection (CombiMag: OZ Biosciences, 
Lipofectamine 2000; Invitrogen). GlyR α1 and β subunit expression constructs were 
transfected at a DNA ratio of 1:10 to promote the formation of heteromeric α1β GlyRs. 32 hrs 
after transfection, cell surface-expression of GlyR β subunits was measured using a cell 
membrane-impermeable reagent Sulfo-NHS-LC-Biotin (Pierce Biotechnology) as previously 
described (Chung et al. 2010).  Proteins in the whole-cell lysates or cell-surface proteins were 
analyzed by Western blotting with an antibody against the GlyR β subunit (1:90; AbCam 
ab123886). An anti β-actin antibody (1:5,000; AbCam) was used as a control to confirm that 
intracellular proteins were not labeled with biotin. The intensity of the immunoreactivity signal 
was quantified using ImageJ (http://rsbweb.nih.gov/ij/). 
 
Fluorescence-based imaging 
Cells were imaged using an automated fluorescence-based screening system using 
EYFPI152L fluorescence quench as an indicator of anion influx. In this technique, iodide flowing 
into the cell binds to and quenches EYFPI152L fluorescence, thus providing an indication of the 
relative activity levels of membrane anion channels (Kruger et al. 2005). Briefly, HEK AD293 
cells were transfected with the plasmid DNAs for wild-type and mutant GlyRs and with the 
DNA for EYFPI152L as described in the results and plated into a 384-well plate. Unless 
otherwise indicated, all GlyR plasmid DNAs were transfected in equimolar ratios for both the 
fluorescence and patch-clamp electrophysiological assays. Within the following 24 - 32 h, the 
culture medium in the wells was replaced with extracellular solution (140 mM NaCl, 5 mM 
KCl, 2 mM CaCl2, 1 mM MgCl2, 10 mM HEPES, and 10 mM glucose, pH 7.4 using NaOH). 
After 30 min, fluorescence images of each well were obtained twice, before and after the 
application of NaI solution (140 mM NaI, 5 mM KCl, 2 mM CaCl2, 1 mM MgCl2, 10 mM 
HEPES, and 10 mM glucose, pH 7.4 using NaOH) containing varying concentrations of 
glycine. Values were pooled from 3 - 4 experiments with three wells each containing >200 
cells. To determine the glycine dose-response curve, an empirical three or four parameter Hill 
equation was fitted by a non-linear least squares algorithm using SigmaPlot 11.0 software. 
Throughout this study, '% quench' is defined as the (initial fluorescence – final fluorescence) × 
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100 / initial fluorescence. Thus, a treatment that completely abolished all fluorescence would 
yield a 100% quench.  
 
Electrophysiology 
Glycine-gated currents were measured using whole-cell patch-clamp electrophysiology at a 
holding potential of -40 mV. Spontaneous single-channel currents were recorded from 
outside-out excised patches, held at -70 mV and in the absence of agonist. HEK AD293 cells 
were transiently transfected with GlyR subunit expression constructs and plated on 
coverslips. Cells were continually superfused with extracellular solution (composition as 
above) and visualized with an inverted fluorescence microscope. Transfected cells were 
identified by co-transfection with an EGFP expression construct. Patch pipettes were pulled to 
final tip resistances of 1 - 4 MΩ (whole-cell) and 6-12 MΩ (outside-out) when filled with a 
standard intracellular solution (145 mM CsCl, 2 mM CaCl2, 2 mM MgCl2, 10 mM HEPES, 10 
mM EGTA, pH 7.4 with CsOH). Whole-cell currents, which were filtered at 1 kHz and digitized 
at 2 kHz, were recorded using an Axon MultiClamp 700B amplifier and pClamp10.2 software. 
Single-channel currents, which were filtered at 5 kHz and digitized at 20 kHz, were recorded 
using an Axon Axopatch 200B and pClamp10.2 software. Drugs diluted in extracellular 
solution were applied to cells or patches via gravity-forced perfusion using parallel small 
tubes. Solution exchange was complete within 200 ms.   
 
Results 
Mutation analysis of GLRB in hyperekplexia 
Individuals with startle disease lacking mutations in GLRA1 and SLC6A5 were screened for 
genetic variation in GLRB coding exons and donor and acceptor splice junctions by Sanger 
DNA sequencing. Sequence variants were assigned as potentially pathogenic after cross-
referencing with known GLRB mutations and common GLRB polymorphisms found in dbSNP 
and the 1000 genomes project. This analysis revealed two novel sequence variants in GLRB 
(Fig. 1A,B, Table 1) in two individuals. Individual 1 harbored a two base missense mutation 
(c.920_921ΔinsGA) resulting in a L285R substitution in the second membrane-spanning 
domain (M2) of the GlyR β subunit. Since this change was found in the heterozygous state 
(Fig. 1A,B) and neither parent carries the mutation, this mutation appears to be de novo. By 
contrast, individual 2 harbored a different missense mutation (c.G996T), resulting in a W310C 
substitution in the third membrane-spanning domain (M3) of the GlyR β subunit. At first 
glance, this mutation appeared to show recessive inheritance, since both parents were 
heterozygous carriers. However, clinical assessments and functional data suggest an 
alternative mechanism of inheritance for this mutation (see below). Recently, another 
recessive mutation c.T596G, resulting in a M177R substitution, was reported (Al-Owain et al. 
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2012) in nine patients in a large family of Saudi Arabian origin with hyperekplexia and 
esotropia, an eye misalignment disorder where one or both eyes turn inward. 
 
Clinical assessment 
Individual 1 is a male of white British descent born at term plus 11 days. His weight and 
height were on the 3rd centile at delivery. Apneas were observed within 40 minutes and 
hypertonia presented within the first hour after birth. These symptoms were severe enough to 
necessitate intubation, his rigidity made ventilation very difficult and startle was prominent 
during this time. The classical nose-tap reflex was also present. Magnetic resonance imaging 
(MRI) revealed subtle brain abnormalities, including a mild increase in signal on T2-weighted 
sequences in the white matter and obvious dentate nuclei; however the basal ganglia had an 
unremarkable appearance. At three months of age stereotyped but unusual dystonic 
posturing movements were observed, including an arm-raising phenomenon that was 
followed by a period of generalized hypertonia during which voluntary movements were 
impossible. At 9 months, his gross motor performance was at the level of 7 months. Although 
this had broadly normalized by 14 months, dystonic movements were still prominent. Minor 
motor delay remained a feature for some time and when last seen he was still hypereflexic 
and had prominent cervical hypertonia, although exaggerated startle was less prominent; he 
also had an alternating strabismus. Now at 9 years, he remains small for his age. He still has 
very mild motor delay, but stiffness is not noticeable and he plays football regularly. He is 
making good progress in school and socially. He is mildly myopic but no longer has 
strabismus. No epileptic seizures have been observed.  
 
Individual 2 is a female of Turkish origin with consanguineous parents. She exhibited neonatal 
hypertonia and irregular breathing necessitating continuous positive airway pressure (CPAP) 
treatment for several days following birth. In addition, she had episodes of neonatal 
bradycardia and an excessive startle reflex, although consciousness was unaltered during 
startle episodes. She had a short period of generalized stiffness following the startle response 
during which voluntary movements were impossible. MRI imaging performed at two months of 
age showed bilateral periventricular cystic changes, in keeping with periventricular 
leucomalacia (necrosis of white matter). She was not dysmorphic and is not currently of small 
stature, at only -1 SD below the mean. At four months of age she had screaming periods 
without a clear loss of consciousness. Concurrently, she had spasms in the jaw and unusual 
movements of her arms. At that time her EEG was normal without focal signs. At 16 months 
of age she had an abnormal EEG with clear high-amplitude spike and wave activity and 
occasional hypsarrythmia (high amplitude and irregular waves and spikes in a background of 
chaotic and disorganized activity). She was treated with nitrazepam and both the seizures 
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and EEG changes disappeared. She currently takes clonazepam and has no further 
symptoms. She does not have gaze palsy, eye movement disorders, nor any apparent 
learning difficulties. According to the family her parents and maternal uncle had ‘light 
symptoms’ in early life. However, further details of their early childhood have been lost over 
time and bound up within cultural restrictions surrounding disclosure. Her older sister 
(untested) has clear symptoms and her younger brother born in 2010 (tested) is also affected. 
The parents (both heterozygous for W310C) do not currently show any hyperekplexia 
symptoms. 
 
Molecular modeling 
M177R, L285R and W310C substitutions were predicted (Table 1) to be damaging or 
probably/possibly damaging using SIFT (Kumar et al. 2009) and Polyphen-2 (Adzhubei et al. 
2010), respectively. These bioinformatics tools predict the possible impact of an amino acid 
substitution on the structure using the conservation of amino acid residues in sequence 
alignments derived from related sequences and machine learning approaches. To gain further 
insights into the potential pathogenic mechanisms of these mutations, we constructed a 
homology model of the human α1β GlyR based on the crystal structure of the GluCl α subunit 
from C. elegans  (Hibbs and Gouaux, 2011). The GluCl structure makes a significantly better 
template for homology modeling of the human GlyR compared to other ligand-gated ion 
channel structures such as Gloeobacter violaceus GLIC (Bocquet et al. 2009), Erwinia 
chrysanthemi ELIC (Hilf and Dutzler, 2009) or the Torpedo marmorata nAChR (Unwin, 2005) 
due to functional similarity (i.e. GluCl is an anion channel) and higher overall sequence 
identity. Profile-profile alignment between the human GlyR subunits and the GluCl α subunit 
generated using MUSCLE (Edgar, 2004) and T-COFFEE (Notredame et al. 2000) resulted in 
44.4% (α1) and 38.9% (β) identity. By contrast, GlyR subunits share lower sequence identity 
with GLIC (α1: 21.8% and β: 24.6%) and different nAChR subunits (α1: 19.7 to 20% and β: 
23.9 to 24.6%). Our GlyR model (Fig. 2A) predicts that L285 in the GlyR β subunit is a pore-
lining residue, projecting a small uncharged, hydrophobic side chain into the ion-channel 
lumen (Fig. 2B). The L285R mutation introduces a significantly larger, positively-charged side 
chain that projects into the pore lumen (Fig. 2C). Because this mutation is de novo and the 
individual is heterozygous for L285R, in theory heteromeric GlyRs could be formed in vivo 
containing 3×wild-type, 1×, 2× or 3× mutant GlyR β subunits (Fig. 2C). Modeling of pore-lining 
residues at a β /β subunit interface (Fig. 3A,B) reveals that L285 is at the 9' 
position in M2, equivalent to L254 in GluCl. This mutation is predicted to disrupt the 
pentameric radial symmetry of the 9' leucine 'hydrophobic girdle', that is essential for 
stabilizing the pore in the closed channel state. Disruption of this girdle is well known to 
induce spontaneous channel activity and/or enhance agonist sensitivity in other Cys-loop 
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receptors (Chang and Weiss, 1998, 1999). In common with GluCl, none of the major pore-
lining residues are charged, with the exception of D271 at the -5' position at the cytoplasmic 
end of M2 (Fig. 3A). This is consistent with different models of anion channel function which 
suggest that the positive electrostatic potential at the base of the pore arises from either: i) 
buried basic residues at the intracellular entrance of the pore (Cymes and Grosman, 2011), 
such as R276 in the M2 0' position in the GlyR β subunit (R252 in the GlyR α1 subunit) or ii) 
oriented peptide dipoles in the M2 α helices (Hibbs and Gouaux, 2011). Given that the 
electrostatic potential at the 0' position strongly influences single-channel conductance 
(Chang and Weiss, 1998, 1999), it is possible that the introduction of a large, positively-
charged residue at the 9' position could have a similar effect.  
 
By contrast, the side-chain of W310 in M3 is part of an intramembrane network of aromatic 
residues (phenylalanine, tyrosine, histidine and tryptophan) contributed by M1, M3 and M4 
(Fig. 4 A,B). Substitution W310C introduces a significantly smaller and shorter side chain into 
this position (Fig. 4C), with a reactive sulfhydryl group. Although we considered that C310 
might form a disulfide bond with C314 in M3, one turn down the helix in our model, the 
distance between the two sulfur atoms (4.6Å) precludes this interaction (Careaga and Falke, 
1992). In addition, disulfide bonds rarely form within the membrane or a reducing intracellular 
environment. Rather, our modeling predicts that the W310C substitution disrupts aromatic 
stacking (Fig. 4B) - a key requirement for correct GlyR assembly and cell-surface trafficking 
(Haeger et al. 2010). 
 
M177 is a hydrophobic amino acid located in the GlyR extracellular domain on a β-sheet (β7). 
The side-chain of this residue forms part of a hydrophobic pocket (Fig. 5A) that is conserved 
within the GluCl structure (Hibbs and Gouaux, 2011), which has an isoleucine at the 
equivalent position. The M177R substitution results in the introduction of a positively-charged, 
hydrophilic side chain into this pocket (Fig. 5B), which is predicted to have a significant effect 
on the folding of the extracellular domain. Although M177/R177 are not predicted to directly 
influence glycine binding (Fig. 5C,D), disruption of the local structure around M177 is 
predicted to cause an indirect effect on agonist binding or signal transduction. For example, 
M177 is located just five residues away from F182, which is involved in a cation-π interaction 
(Pless et al. 2008) with the amino group of glycine. 
 
Cell-surface biotinylation assays 
To establish whether the GlyR β subunit mutants impaired cell-surface expression of GlyRs, 
we carried out cell-surface biotinylation assays for heteromeric α1β GlyRs (Chung et al. 2010), 
detecting β-subunit expression using a specific antibody. Note that in the absence of the GlyR 
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α1 subunit, the GlyR β subunit is not expressed at the cell surface in HEK293 cells, but is 
retained in the rough endoplasmic reticulum (Kirsch et al. 1995). The M177R, L285R and 
W310C mutant polypeptides were all detected at equivalent levels to the wild-type GlyR β 
subunit in total cell lysates, suggesting that they synthesized correctly and are not prone to 
rapid degradation (Fig. 6A). However, quantification of the biotinylation of heteromeric cell-
surface α1β GlyRs revealed significant decreases in cell-surface expression of α1β
L285R and 
α1β
W310C subunit GlyRs (Fig. 6A, B) to 27.3 ± 1.1% for L285R and 21.5 ± 8.3% for W310C of 
the level of wild-type α1β GlyRs. By contrast, α1β
M177R GlyRs had a similar level of cell-surface 
expression (104 ± 2.2%) when compared to wild-type α1β GlyRs. 
 
Functional analysis using EYFP Cl- sensors and electrophysiology 
HEK AD293 cells were co-transfected with expression constructs encoding the GlyR α1 
subunit together with each GlyR β subunit mutant. To reproduce the heterozygous state, GlyR 
α1 was co-transfected with wild-type and mutant GlyR β subunits. We initially employed the 
EYFP assay (Kruger et al. 2005; Chung et al. 2010) to provide an indication of the anion influx 
rate through the recombinant GlyRs. The advantage of this approach is that responses of 
large numbers of cells can be averaged, thus permitting the reliable quantitation of small 
changes in the current fluxing capacity of functional GlyRs. Glycine dose-response 
relationships (Fig. 7A,B) revealed that the maximal fluorescence quench was significantly 
reduced for α1β
L285R, α1ββ
L285R, α1β
W310C and α1ββ
W310C GlyRs relative to wild-type α1β GlyRs 
(Fig. 7C), suggesting that mutations L285R and W310C reduce anion flux rates in both the 
homozygous and heterozygous states. We also found that the reduction of Cl- flux was 
dependent on the ratio of wild-type GlyR α1 subunit (the amount was held constant) to mutant 
GlyR β subunits (Fig. 7D), with significantly reduced Cl- flux observed with increasing levels of 
βW310C expression. Given that α1β GlyRs exist in an invariant β stoichiometry (Yang et 
al. 2012), we infer that increasing the βW310C α1 subunit ratio increases the proportion of 
heteromeric GlyRs, which in turn reduces functional GlyR expression. These data are 
consistent with our biotinylation assays, and suggest βW310C subunits prevent wild-type GlyR 
subunits from trafficking to the cell surface. EC50 values for wild-type α1β, α1β
L285R and 
α1β
W310C GlyRs were 5 ± 1, 4 ± 1, 13 ± 2 µM, respectively (Table 2), suggesting that the 
L285R and W310C mutations do not substantially alter the agonist sensitivity of recombinant 
α1β GlyRs reaching the cell surface. 
 
To test if the mutated β subunits incorporate into functional GlyRs, the pore blocker lindane 
was applied. Lindane potently inhibits homomeric α subunit GlyRs, but has almost no effect 
on heteromeric αβ subunit GlyRs (Islam and Lynch, 2012). GlyRs containing βL285R or βW310C 
subunits exhibited a reduced sensitivity to lindane, indicating that receptors incorporating 
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these mutant subunits are functionally expressed at the cell surface (Fig. 7E). Since artificial 
mutations at the 9' position in GABAC and GABAAR subunits result in spontaneously-opening 
channels (Chang and Weiss, 1998, 1999), we also investigated whether α1β
L285R GlyRs 
showed this property, by quantifying the fluorescence change in the absence of glycine. Both 
α1β
L285R and α1ββ
L285R GlyRs showed a significant increase in quench relative to heteromeric 
α1β GlyRs, which is suggestive of spontaneous activity (Fig. 7F). Even in the absence of 
glycine, the quench observed was >20%. By contrast, the quench observed in the absence of 
glycine for α1β
W310C containing GlyRs was only slightly higher than for wild-type GlyRs, 
suggesting that these GlyRs do not show spontaneous gating. Averaged results obtained 
using the EYFP Cl- flux assay for L285R and W310C are summarized in Table 2. 
 
Electrophysiology was subsequently used to analyze the effects of the L285R and W310C 
mutations on GlyR function in greater detail. Dose-response relationships confirmed that the 
agonist sensitivity for GlyRs containing either mutated subunit did not change relative to wild-
type α1β heteromers (Fig. 8A,B). As in the EYFP assays, the presence of the GlyR β subunit 
was confirmed by applying lindane (Fig. 8A). Spontaneous activity of α1β
L285R-containing 
GlyRs could be inhibited by the pore-blocker picrotoxin (Fig. 8C). However, due to the 
resistance of heteromeric α1β GlyRs to picrotoxin (Pribilla et al. 1994), this inhibition was 
typically only about 100 pA. Single-channel recordings in the absence of glycine confirmed 
the spontaneous activity of α1β
L285R GlyRs (Fig. 8D). Averaged over four patches, mean open 
probability in the absence of applied glycine was 0.04 ± 0.01. The maximal unitary 
conductance level (denoted by γ2 in Fig. 8D) was 49.4  ± 0.7 pS with an additional sub-
conductance level (γ1) at 23.9 ± 0.3 pS (both n=4 patches). The dominant 49 pS level 
corresponds closely to that observed in wild-type α1β GlyRs (44 pS) (Bormann et al. 1993), 
indicating that the L285R substitution does not affect single-channel conductance. To 
investigate the properties of α1β
W310C GlyRs, whole-cell recordings were made from >200 
EGFP-expressing cells that had been transfected with both α1 and β
W310C subunits in a 1:10 
molar ratio. Only 20 of these cells expressed glycine-gated currents, with only two of the 20 
expressing lindane-insensitive GlyRs, suggesting a predominance of α1β
W310C GlyRs in the 
cell membrane. In both of these cells, the maximal current amplitude was significantly 
reduced relative to wild-type GlyRs (Fig. 8E), suggesting a reduction in either maximum open 
probability, single-channel conductance, and/or the number of functional channels expressed 
in the plasma membrane. Based on the biotinylation results, we can conclude that the 
reduced current amplitude is at least partly caused by reduced cell-surface expression. The 
properties of whole-cell currents mediated by α1β
L285R and α1β
W310C GlyRs are summarized in 
Table 3. 
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The M177R mutant resulted in both a reduction of maximal fluorescence quench (Fig. 9A,B) 
and a rightward shift in the EC50 value for glycine (Fig. 9A) from 17 ± 5 μM for wild-type α1β 
GlyRs to 45 ± 14  μM α1ββ
M177R and 64 ± 13 μM for α1β
M177R GlyRs (Table 4).  Heteromeric 
α1β
M177R GlyRs exhibited a slightly reduced sensitivity to lindane (Fig. 9C). However, the 
reduced glycine sensitivity indicates that receptors incorporating the βM177R subunit are 
expressed at the cell surface. Using patch-clamp electrophysiology, we confirmed that the 
EC50 value of α1β
M177R GlyRs was significantly increased from 39 ± 4 μM for wild-type α1β 
GlyRs to 162 ± 3 μM for α1β
M177R GlyRs (Fig. 9D,E) and that peak current magnitudes relative 
to wild-type α1β heteromers were significantly reduced (Fig. 9D,E, Table 3). We infer from 
these results that βM177R was incorporated efficiently into functional heteromeric GlyRs. 
However, incorporation of βM177R did not render GlyRs completely insensitive to lindane (Fig. 
9E, inset). 
 
Discussion 
This study reports the identification and functional characterization of novel mutations in the 
GlyR β subunit gene (GLRB) that reveal new pathogenic mechanisms underlying startle 
disease/hyperekplexia. We identified two new missense variants in GLRB causing L285R and 
W310C substitutions in membrane spanning domains M2 and M3. Using molecular modeling, 
cell-surface biotinylation assays, an EYFP-based anion flux assay and patch clamp 
electrophysiology, we were able to establish the likely pathogenic mechanisms for L285R and 
W310C, as well as a third mutation - M177R - recently reported (Al-Owain et al. 2012) in a 
large Saudi Arabian family with hyperekplexia. L285R is a de novo mutation, i.e. not found in 
either parent, which reduces peak current magnitude by reducing the cell-surface trafficking of 
GlyRs. Since the L285R substitution disrupts the integrity of the 9' leucine hydrophobic girdle 
that stabilizes the channel closed state (Chang and Weiss, 1998, 1999), it was perhaps 
inevitable that α1β
L285R GlyRs were also associated with leak conductance indicating tonic 
channel opening. Since we recently described a dominant GlyR α1 subunit mutation in the 
large extracellular domain (Y128C) with a leak conductance (Chung et al. 2010), this 
pathogenic mechanism is an emerging theme in startle disease. Introduction of the pore-lining 
9' arginine residues might also have been expected to affect unitary conductance (Cymes and 
Grosman, 2011). However, we found that the dominant maximum conductance level of 
α1β
L285R GlyRs (49 pS) was similar to that of α1β GlyRs (44 pS) (Bormann et al. 1993). 
 
On first impressions, W310C also appeared to be a classical recessive hyperekplexia 
mutation, interfering with the formation of cell-surface GlyRs, rather than affecting glycine 
sensitivity. However, detailed analysis revealed both novel pathogenic mechanisms and 
mode of inheritance for this missense mutation. Molecular modeling revealed that W310 is a 
 14 
key residue involved in a hydrophobic stack formed by aromatic residues in M1, M3 and M4 
that determines GlyR subunit stoichiometry (Haeger et al. 2010). The W310C substitution in 
M3 is predicted to act by destabilizing intramembrane packing of α-helices, a result that is in 
accord with our functional studies, which show compromised cell-surface expression of 
α1β
W310C and α1ββ
W310C GlyRs and the formation of a significant proportion of GlyR α1 subunit 
homomers even in the presence of a ten-fold excess of βW310C. However, we cannot rule out 
the possibility that reductions in channel open probability or single-channel conductance may 
also have contributed to the reduced current-carrying capacity of these mutant receptors. The 
inheritance of this mutation is of significant clinical interest, since mild startle symptoms were 
reported in both parents. This mutation is likely to represent a case of incomplete dominance, 
i.e. a mutation that has an intermediate effect in heterozygous carriers. This mechanism is 
supported by our functional data, since the maximal quench was significantly reduced for both 
α1β
W310C and α1ββ
W310C GlyRs compared to wild-type α1β GlyRs. It is tempting to speculate 
that mutations such as W310C in GLRB might form the genetic basis for 'minor startle', an 
excessive startle response in the absence of hypertonia. This phenomenon has been 
reported (Tijssen et al 1995, 1996, 2002) in several hyperekplexia studies, but even though 
'major' and 'minor' startle can occur together in the same family, the genetic basis remains 
unresolved and it has been assumed by some to be a 'normal but pronounced startle 
response'. Our study suggests that certain GlyR mutations may show incomplete dominance, 
providing a potential genetic explanation for mild startle in heterozygous carriers. This mild 
startle is predicted to be more common for GLRB mutations, since the likelihood of a 
heterozygous carrier being able to synthesize fully wild-type GlyRs with a 2α1:3β 
stoichiometry when carrying a defective GLRA1 allele is 1 in 4, versus 1 in 8 for a defective 
GLRB allele.  
 
The remaining GLRB substitution we studied in detail was M177R, which both molecular 
modeling and functional studies suggest does not disrupt cell-surface trafficking, but interferes 
indirectly with agonist binding, by disrupting a local β-sheet fold in the large extracellular 
domain. M177 is located just five residues away from F182, which participates in a cation-π 
interaction with glycine (Pless et al. 2008). Thus, the pathogenic mechanism for M177R 
resembles that of a previously reported mutation G229D, which also displayed a reduced 
EC50 for glycine (Rees et al. 2002). 
 
Our ongoing genetic screening program has recently revealed numerous recessive mutations 
in the genes encoding the GlyR α1 subunit (GLRA1) and GlyT2 gene (SLC6A5). However, 
one conundrum is why so few GLRB mutations have been reported in startle disease. In part, 
this may be historical: GLRA1 was the first startle disease gene to be discovered in 1993 
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(Shiang et al. 1993) and mutations in this gene explain the majority of cases of dominant 
hyperekplexia. By contrast, mutations in GLRB and SLC6A5 were first reported in 2002 and 
2006, respectively (Rees et al. 2002, 2006). This 'head start' for GLRA1 is reflected in the 
NCBI gene-testing registry. Of the clinical laboratories world-wide offering screening for startle 
disease, seven screen for GLRA1 mutations, three offer screening for GLRB and only one 
offers screening for SLC6A5 mutations. However, this testing does not reflect the true 
prevalence of disease alleles - for example, we recently reported twenty new pathogenic 
sequence variants for GlyT2 in 17 index cases (Carta et al. 2012), as well as a new dominant 
GlyT2 mutation found in multiple families (Giménez et al. 2012). These studies certainly 
suggest that SLC6A5 is a major startle disease gene. Methodology may also play a role: 
initial attempts at screening GLRB used single-strand conformation polymorphism (SSCP) or 
bi-directional di-deoxy fingerprinting (ddF) methods (Milani et al. 1998; Rees et al. 2002), 
which have variable sensitivity for mutation detection. By contrast, our study and two other 
recent reports (Al-Owain et al. 2012; Lee et al. 2012) have used Sanger DNA sequencing - 
currently the method of choice for mutation detection - although this is likely to be superseded 
in time by targeted next-generation sequencing panels (Lemke et al. 2012). The extended 
clinical phenotype in these cases, encompassing breathing difficulties/severe neonatal apnea 
episodes, bradycardia and developmental delay is likely to be explained by the loss of 
multiple synaptic GlyR subtypes in vivo, i.e. α2β, α3β as well as the predominant α1β isoform. 
In this regard, it is noteworthy that GlyR α3 subunit knockout mice were recently shown to 
have an irregular respiratory rhythm, due to loss of 5HT1A-mediated modulation of GlyRs in 
the brainstem (Manzke et al. 2011). 
 
It is also clear that there are key differences in the relative damage caused by equivalent 
missense changes in GlyR α1 versus GlyR β subunits. For example, dominant startle disease 
mutations in GLRA1 predominantly affect key amino acid residues in the M2 domain and M2-
M3 linker region of the GlyR α1 subunit (Fig. 1A), where they act to uncouple ligand-binding 
from channel gating. Shan et al. (2011) recently demonstrated that GlyR function is less 
sensitive to hyperekplexia-mimicking mutations introduced into the M2-M3 loop of the GlyR β 
subunit than the α1 subunit. This suggests that the GlyR α1 M2-M3 loop dominates the β 
subunit in gating heteromeric α1β GlyRs and in turn that it is perhaps unlikely that a set of 
equivalent dominant mutations in the M2-M3 linker (Fig. 1A) will be found in GLRB. This is 
consistent with our finding that GlyRs containing the L285R mutant exhibit an EC50 that is 
similar to wild-type, confirming that the  subunit is not the major mediator of signal 
transduction in heteromeric GlyRs. Rather, the GLRB mutations found to date appear to 
cluster near key glycine binding residues (M177R, G229D) or are found in membrane-
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spanning domains M1-M3 (Fig. 1B), where they disrupt receptor trafficking and affect ion-
channel function (L285R) or hydrophobic side-chain stacking (W310C). 
 
Other potential pathogenic mechanisms for GLRB include protein truncation (via deletion, 
frameshift, splice site or nonsense mutations) or mutations in the gephyrin-binding site 
located between M3 and M4 (Fig. 1B). At least in vitro, artificial missense mutations affecting 
single amino acids, such as F398A in the GlyR β subunit gephyrin-binding motif are capable 
of significantly impairing GlyR β-gephyrin interactions (Kim et al. 2006), which would in turn 
abolish GlyR clustering at synapses. Based on our previous experience with GLRA1 and 
SLC6A5, we consider it likely that a number of recessive SNVs remain to be discovered in 
GLRB. Based on the discovery of four new GLRB variants associated with hyperekplexia in 
this year alone (Al-Owain et al. 2012; Lee et al. 2012, this study), we recommend that GLRB 
should have equal status alongside GLRA1 and SLC6A5 in the molecular genetic diagnosis 
of startle disease. 
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Figure legends 
 
Figure 1. Human GlyR β subunit mutations identified in individuals with startle 
disease/hyperekplexia. Amino acid sequences of the human GlyR α1 and β subunits 
indicating the positions of putative membrane-spanning domains (grey shaded boxes) defined 
by alignments with GluCl (Hibbs and Gouaux 2011) and amino-acid residues affected by 
hyperekplexia mutations. Mutation key: dominant mutation: red; recessive: blue; de novo: 
orange. Green lettering denotes key ligand-binding residues in the GlyR α1 and β subunits. 
Purple lettering denotes the gephyrin-binding motif between M3 and M4 of the GlyR β 
subunit. 
 
Figure 2. Molecular modeling of the human α1β GlyR and mutation L285R. (A) Side view 
of the molecular model of the human GlyR α1β pentamer showing α1 subunits in gold and β 
subunits in blue. The positions of the inner and outer membrane surfaces are indicated by 
grey spheres. (B) Orthographic view of the GlyR α1β pentamer, showing the relative position 
of the L285 side chain in the ion-channel pore. (C) Panels depicting the multiple GlyR 
isoforms that could be formed on co-expression of wild-type and mutant GlyR β subunits 
harboring the L285R substitution. A red plus sign denotes the positive charge carried by the 
side-chain of R285. 
 
Figure 3. Mutation L285R inserts a charged residue into the GlyR ion-channel pore. (A) 
Sequence alignment of M2 of GluCl with GlyR α1 and β subunits. Relative positions of 
residues that line the Cl- channel are indicated with black circles and residue numbers 
indicated for GluCl and the GlyR β subunit. Residues carrying presumed positive and 
negative charges are colored red and blue, respectively, although it should be noted that the 
protonation state of these residues at physiological pH has not been established. The position 
of L285 is indicated by grey highlighting. (B,C) Schematic diagrams depicting two GlyR β 
subunit M2 α-helices and residues lining the Cl- channel for wild-type L285 (B) and the R285 
mutant (C). Blue spheres represent the predicted internal volume of the ion channel and side-
chains are shown for pore-lining residues. The L285R substitution is predicted to create a 
premature narrowing of the pore at the 9' position and inserts a positively charged residue (+) 
into an α helix that is uncharged, with the exception of D271 on the cytoplasmic face of the 
ion-channel pore. 
 
Figure 4. Mutation W310C disrupts hydrophobic stacking of membrane-spanning 
domains M1-M3. (A) Cutaway view from the extracellular side of the GlyR β subunit showing 
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how the side-chain of residue W310 in M3 contributes to a hydrophobic stack of aromatic 
residues contributed by membrane-spanning domains M1, M3 and M4. Hydrophobic side-
chains of residues predicted to be involved in this stack are colored according to membrane-
spanning domain: M1: red; M3: yellow and M4: blue. (B) Mutation W310C results in the loss 
of the aromatic, hydrophobic side chain of tryptophan and replacement with the shorter, 
reactive cysteine sulfydryl side chain. (C-F) Top and side views showing the hydrophobicity of 
individual residues in the stack by coloring the atom surfaces. Hydrophobic surfaces are 
depicted in orange, hydrophilic in blue and white indicates neutral polarity. The W310C 
substitution is predicted to disrupt the hydrophobic stack, altering the tertiary fold of the 
membrane-spanning domains and introduce an empty space (F, circled with a dashed line). 
Disulfide bond formation is unlikely, since this is rare within the membrane or an intracellular 
environment and the only adjacent sulfur atom (C314 in M3) is 6.4Å away from C310 sulfur. 
 
Figure 5. Mutation M177R disrupts local structure of a -sheet in the N-terminal 
extracellular domain. (A, B) Side views of part of the GlyR  subunit extracellular domain 
showing the location of M177 (A) and R177 (B, red lettering) within a -sheet structure. The 
polarity of the surface residues is shown with hydrophobic residues depicted in orange, 
hydrophilic in blue and white indicating neutral polarity. (C) Rotating the model 180 
horizontally shows that M177 is located close to F182, which is involved in a cation-π 
interaction with the amino group of glycine. (D) Top view of M177, relative to the ligand-
binding domain, rotated 90 vertically from B. Thus, mutation M177R is predicted to result in 
the loss of a hydrophobic side-chain and replacement with a positively-charged side chain. 
This substitution is predicted to disturb the local fold of the extracellular domain and have a 
knock-on effect for positioning of the critical ligand-binding residue F182. 
 
Figure 6. Cell-surface biotinylation assays for GlyR β subunit mutations. (A) Cell-
surface biotinylation assays on heteromeric α1β GlyRs expressed in HEK293 cells revealed 
that all three GlyR β subunit mutants (M177R, L285R and W310C) were expressed at similar 
levels in whole-cell protein expression (total) compared to an actin control. However, 
mutations L285R and W310C revealed markedly reduced cell-surface protein expression 
(surface) compared to wild-type or the M177R mutant. 70 μg of protein lysates were loaded in 
the each lane. (B) Quantification of cell surface and whole cell expression of the GlyR β 
subunit mutants using ImageJ software, with values expressed as a percentage of wild-type 
GlyR β subunit expression. p-values were calculated relative to wild-type GlyR β expression 
using an unpaired t-test; *** = p < 0.001. 
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Figure 7. Functional characterization of human GlyR βL285R and βW310C mutations using 
the EYFP assay. (A,B) Mean glycine dose-response curves for α1, α1β, α1β
L285R, α1ββ
L285R, 
α1β
W310C and α1ββ
W310C GlyRs. The percentage quench is plotted against the applied glycine 
concentration (µM). Averaged parameters of best fit to dose-response curves are summarized 
in Table 2. (C) Maximal changes in fluorescence. ΔFmax is the initial fluorescence value minus 
the final fluorescence value and is represented in fluorescence units. p-values were 
calculated relative to α1β GlyR heteromers by unpaired t-test: * p < 0.05, ** p < 0.01, *** p < 
0.001. (D) Maximal changes in fluorescence for GlyR subunits transfected in different α:β 
ratios while the amount of α1 transfected was held constant. * p < 0.05 by unpaired t-test. (E) 
Inhibition by 100 µM lindane. The inhibition of currents activated by 10 µM glycine by 100 µM 
lindane is represented as a percentage reduction of the control maximal fluorescent quench. 
p-values were calculated relative to GlyR α1 homomers by unpaired t-test: * p < 0.05, ** p < 
0.01, *** p < 0.001. (F) Fluorescent quench in the presence of sodium iodide (no glycine). p-
values were calculated relative to GlyR α1β heteromers by unpaired t-test: * p < 0.05, ** p < 
0.01, *** p < 0.001. All data points displayed in this figure represent the average quench from 
four experiments comprising three wells each with > 200 cells per well. 
 
Figure 8. Functional characterization of human GlyRs containing βL285R and βW310C 
using electrophysiology. (A) Sample glycine dose-response traces of α1β, α1β
L285R and 
α1β
W310C GlyRs. Filled bars indicate the applied glycine concentrations in µM and non-filled 
bars the application of 100 µM lindane. The effect of 100 µM lindane on homomeric α1 subunit 
GlyRs is included as a control. (B) Normalized glycine dose-response curves for the GlyRs 
shown in panel A. (C) Inhibition of leak currents in α1β
L285R GlyRs by 100 µM picrotoxin (PTX). 
The inward current transient was always observed (n=5 cells). (D) Spontaneous single-
channel currents for α1β
L285R GlyRs. Most openings were of 2 - 10 ms duration as illustrated in 
Patch 1. Occasionally, with multiple channels in the patch, longer activations were also 
observed, as in Patch 2. (E) Mean currents activated by 100 µM glycine in cells expressing 
α1β GlyRs in a 1:1 ratio relative to those in cells expressing α1β
W310C GlyRs in a 1:10 ratio. p-
values were calculated relative to GlyR α1β heteromers by unpaired t-test: ** p < 0.01.  
 
Figure 9. Functional characterization of human GlyRs containing βM177R using the EYFP 
assay and electrophysiology. (A) Mean glycine dose-response curves for α1, α1β, α1β
M177R 
and α1ββ
M177R GlyRs using the EYFP assay. The percentage quench is plotted against the 
applied glycine concentration (µM). Averaged parameters of best fit to dose-response curves 
are summarized in Table 3. All data points represent the average quench from four 
experiments comprising three wells each with > 200 cells per well. (B) Maximal changes in 
fluorescence. ΔFmax is the initial fluorescence value minus the final fluorescence value and is 
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represented in fluorescence units. p-values were calculated relative to α1β GlyR heteromers 
by unpaired t-test: * p < 0.05, *** p < 0.001. (C) Inhibition by 100 µM lindane. The inhibition of 
currents activated by 100 µM glycine by 100 µM lindane is represented as a percentage 
reduction of the control maximal fluorescent quench. p-values were calculated relative to 
GlyR α1 homomers by unpaired t-test: ** p < 0.01, *** p < 0.001. (D) Normalized glycine dose-
response results using whole-cell patch-clamp electrophysiology for the GlyRs shown in panel 
E. The normalized maximal currents of cells transfected with the indicated plasmid vectors 
are plotted against the applied glycine concentration (µM). (E) Sample glycine dose-response 
traces. Filled bars indicate the applied glycine concentration in µM and non-filled bars the 
application of 100 µM lindane.  
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Position Exon Protein 
Precursor / 
mature 
Type SIFT Polyphen-2 Overall 
Prediction 
c.T596G 6 
M199R /  
M177R 
Missense  Damaging (0) 
Possibly damaging 
(0.802) 
Pathogenic  
 c.G752A 
 
IVS5+5G>A 
8 
 
- 
  G251D / 
G229D 
- 
 Missense 
 
Splice site 
Damaging (0) 
 
- 
Probably damaging 
(1.0) 
- 
Pathogenic 
 
Pathogenic 
c.920_921ΔIn
sGA 
9 
L307R / 
L285R 
Missense Damaging (0) 
Probably damaging 
(0.997) 
Pathogenic 
c.G996T 9 
W332C / 
W310C 
Missense Damaging (0) 
Probably damaging 
(0.999) 
Pathogenic 
c.C1028T 9 
S343F /  
S321F 
Missense  Damaging (0) 
Probably damaging 
(0.990) 
Pathogenic 
 
 
 
Table 1. Single nucleotide variants in GLRB associated with startle 
disease/hyperekplexia. Mutations G229D/IVS5+5G>A, M177R, and S321F were reported 
previously (Rees et al. 2002; Al-Owain et al. 2012; Lee et al. 2012). Panel: DNA sequence 
electropherograms for the two novel mutations (c.920_921ΔInsGA/L285R and 
c.G996T/p.W310C) reported in this study. Bioinformatics analysis was conducted using SIFT 
(Kumar et al. 2009) with ENSP00000264428 and Polyphen-2 (Adzhubei et al. 2010). 
 
 
EYFP assay 
EC50 (µM) nH 
ΔFmax 
(FU) 
cellsquench 
(%) 
LINinh  
(%) 
n 
α1 8 ± 1 1.7 ± 0.1 44 ± 1 94 ± 2 111 ± 4 12 
α1β 5 ± 1 3.9 ± 2.2 44 ± 2 96 ± 2 38 ± 2
*** 12 
α1β
L285R 4 ± 1 0.9 ± 0.1* 19 ± 2*** 86 ± 7 6 ± 7*** 12 
α1ββ
L285R 4 ± 1 0.9 ± 0.1* 19 ± 2*** 83 ± 5 14 ± 7*** 12 
α1β
W310C 13 ± 2* 4.3 ± 1.8 32 ± 3* 81 ± 5* 51 ± 10** 12 
α1ββ
W310C 11 ± 1** 5.1 ± 1.5 32 ± 1** 90 ± 1* 32 ± 12*** 12 
 
Table 2. Properties of human GlyRs containing βL285R and βW310C subunits using the 
EYFP assay. EC50 values, Hill coefficients (nH), the maximal fluorescence changes (ΔFmax), 
the maximal percentages of quenched cells (cellsquench) and the inhibition of 10 µM glycine 
currents by 100 µM lindane (LINinh) are represented. p-values were calculated relative to GlyR 
α1β subunit heteromers except for inhibition by lindane, which was compared to GlyR α1 
subunit homomers by unpaired t-test: * p < 0.05, ** p < 0.01, *** p < 0.001.  
Tables 1-4
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Table 3. Properties of α1β, α1β
L285R, α1β
W310C and βM177R GlyRs using whole-cell patch-
clamp electrophysiology. EC50 values, Hill coefficients (nH) and the maximal currents (Imax) 
are represented. p-values were calculated relative to the wild-type α1β subunit GlyRs by 
unpaired t-test: ** p < 0.01, *** p < 0.001. 
 
 
EYFP assay 
EC50 
(µM) 
nH 
ΔFmax 
(FU) 
cellsquenc
h (%) 
LINinh  
(%) 
n 
α1 25 ± 5 1.5 ± 0.1 46 ± 2 97 ± 1 92 ± 5 12 
α1β 17 ± 5 1.7 ± 0.1 50 ± 1 96 ± 1 42 ± 6*** 12 
α1β
M177R 64 ± 13* 3.4 ± 1.9 29 ± 1*** 81 ± 2*** 54 ± 8* 12 
α1ββ
M177R 45 ± 14 3.4 ± 1.9 31 ± 2* 84 ± 2*** 60 ± 7** 12 
 
Table 4. Properties of α1β
M177R GlyRs using the EYFP assay. EC50 values, Hill coefficients 
(nH), the maximal fluorescence changes (ΔFmax), the maximal percentages of quenched cells 
(cellsquench) and the inhibition of 100 µM glycine currents by blocking with 100 µM lindane 
(LINinh) are represented. p-values were calculated relative to GlyR α1β subunit heteromers 
except for inhibition by lindane, which was compared to GlyR α1 subunit homomers by 
unpaired t-test: * p < 0.05, ** p < 0.01, *** p < 0.001.  
 
 
Whole-cell patch-clamp electrophysiology 
EC50 (µM) nH Imax (nA) n 
α1β 39 ± 4 2.4 ± 0.2 14 ± 3 5 
α1β
L285R 49 ± 7 1.2 ± 0.1** 9 ± 4 3 
α1β
W310C 28, 58 1.7, 4.0 0.22, 0.15 2 
α1β
M177R 162 ± 3*** 2.2 ± 0.1 8 ± 1 5 
Supplementary information 
 
Table 1: PCR primers for GLRB exon amplification 
 
Exon 1 forward TGTAAAACGACGGCCAGTCTGTCGGGACACCTCTTC 
 reverse CAGGAAACAGCTATGACCTTCCGCAAAGGCGTCTATTC 
Exon 2 forward TGTAAAACGACGGCCAGTTTTGGGTAGTAATGCTTATACTC 
 reverse CAGGAAACAGCTATGACCCTTCATAAACCACCTTACTT 
Exon 3 forward TGTAAAACGACGGCCAGTGCAGTCTTTCCTCCCAATGA 
 reverse CAGGAAACAGCTATGACCAAACCCATTGCGGATGT 
Exon 4 forward TGTAAAACGACGGCCAGTACATGTTATACTGAGACCATAGAT 
 reverse CAGGAAACAGCTATGACCTATACTAGGAAAGGGCATGGATTA 
Exon 5-6 forward TGTAAAACGACGGCCAGTGGGCCGAATAAGTTCTTAAA 
 reverse CAGGAAACAGCTATGACCAGTAGAATGTATTACCCAGAC 
Exon 7 forward TGTAAAACGACGGCCAGTTGACCATGGGTTTTACCTCT 
 reverse CAGGAAACAGCTATGACCCTACTCTCCCCTTGGCT 
Exon 8 forward TGTAAAACGACGGCCAGTACCGTTTCCAGGTCTGTC 
 reverse CAGGAAACAGCTATGACCACACCGAAATTGGTGGCTA 
Exon 9 forward TGTAAAACGACGGCCAGTTTGTTCATGGGTCATTGGAAGTTA 
 reverse CAGGAAACAGCTATGACCCACATACACAAAGGTGTCT 
Exon 10 forward TGTAAAACGACGGCCAGTCGTTTGAAGAGATGTGT 
 reverse CAGGAAACAGCTATGACCTCCAAAATGCAATGTTGCTA 
